NGS reveals HER2 amplification in a clinically relevant proportion of tumors and in a variety of tumor types, and HER2-targeted therapy may confer clinical benefit in tumor types beyond those for which HER2 inhibitors are approved. The gene discussed is ERBB2; the disease is neoplasm.